Cargando…

Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia

BACKGROUND: Olanzapine (OLZ) treatment is associated with a high risk of weight gain, and may cause abnormalities in glycolipid metabolism. Therefore, the underlying mechanism of OLZ-related weight gain is needed to clarify but not yet been adequately determined. In recent years, adipocytokines such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsuneyama, Nobuto, Suzuki, Yutaro, Sawamura, Kazushi, Sugai, Takuro, Fukui, Naoki, Watanabe, Junzo, Ono, Shin, Saito, Mami, Someya, Toshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773092/ https://www.ncbi.nlm.nih.gov/pubmed/26930407 http://dx.doi.org/10.1371/journal.pone.0149518

Ejemplares similares

Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia
por: Tajiri, Misuzu, et al.
Publicado: (2018)

Serum cortisol and insulin-like growth factor 1 levels in major depressive disorder and schizophrenia
por: Arinami, Hiroshi, et al.
Publicado: (2023)

Role of insulin-like growth factor 1, sex and corticosteroid hormones in male major depressive disorder
por: Arinami, Hiroshi, et al.
Publicado: (2021)

Psychiatrists' Attitudes toward Metabolic Adverse Events in Patients with Schizophrenia
por: Sugawara, Norio, et al.
Publicado: (2014)

Influence of Atomoxetine on Relationship Between ADHD Symptoms and Prefrontal Cortex Activity During Task Execution in Adult Patients
por: Sugimoto, Atsunori, et al.
Publicado: (2021)

Association Between the Number of Remaining Teeth and Body Mass Index in Japanese Inpatients with Schizophrenia
por: Otake, Masataka, et al.
Publicado: (2022)

The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder: A non-randomized prospective interventional study
por: Sugimoto, Atsunori, et al.
Publicado: (2021)

High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey
por: Ono, Shin, et al.
Publicado: (2018)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2020)

Attitudes toward metabolic adverse events among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2016)

High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia: a nationwide survey
por: Sugai, Takuro, et al.
Publicado: (2015)

Exclusive Breastfeeding Is Not Associated with Maternal–Infant Bonding in Early Postpartum, Considering Depression, Anxiety, and Parity
por: Fukui, Naoki, et al.
Publicado: (2021)

High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey
por: Sugai, Takuro, et al.
Publicado: (2016)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

Weight gain with olanzapine: Drug, gender or age?
por: Jain, Sanjay, et al.
Publicado: (2006)

The Effect of Ranitidine on Olanzapine-Induced Weight Gain
por: Ranjbar, Fatemeh, et al.
Publicado: (2013)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2017)

Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain
por: Wang, Li, et al.
Publicado: (2020)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety
por: Sakamaki, Akira, et al.
Publicado: (2019)

Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder
por: Lipkovich, Ilya, et al.
Publicado: (2008)

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
por: Huang, Jing, et al.
Publicado: (2020)

Body Weight and Plasma Levels of Ghrelin and Leptin during Treatment with Olanzapine
por: Kim, Bong-Jo, et al.
Publicado: (2008)

Factor Structure and Measurement Invariance of the Hospital Anxiety and Depression Scale Across the Peripartum Period Among Pregnant Japanese Women
por: Ogawa, Maki, et al.
Publicado: (2021)

Depression, Anxiety and Primiparity are Negatively Associated with Mother–Infant Bonding in Japanese Mothers
por: Motegi, Takaharu, et al.
Publicado: (2020)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Corrigendum: Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
por: Huang, Jing, et al.
Publicado: (2020)

Olanzapine- induced metabolic syndrome pathogenesis: Hypothalamic “leptin resistance” or “pomc resistance”?
por: Veneziani, F., et al.
Publicado: (2021)

Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
por: Hu, Yueshan, et al.
Publicado: (2014)

Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment
por: Lian, Jiamei, et al.
Publicado: (2014)

Comparison of olanzapine-induced weight gain and metabolism abnormalities between topiramate and vitamin C in patients with schizophrenia: a preliminary study
por: Zhang, Jinling, et al.
Publicado: (2023)

Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
por: Correll, Christoph U, et al.
Publicado: (2023)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
por: Katshu, Mohammad Zia Ul Haq, et al.
Publicado: (2018)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse
por: Morgan, Andrew P., et al.
Publicado: (2014)

Olanzapine: Worsening of obsessive compulsive disorder and weight gain: case report
Publicado: (2022)

Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain
por: Qian, Li, et al.
Publicado: (2023)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_j6ss5lsuvb9nfmgnfeklvps296